Cytokinetics has presented results from Phase I and Phase IIa clinical trials of omecamtiv mecarbil, a novel cardiac myosin activator indicated for the potential treatment of heart failure in hospital and outpatient settings.
The trials, being conducted by Amgen in collaboration with Cytokinetics, are designed to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic profiles of both intravenous and oral formulations of the drug.
Both trials provided evidence for the translation into humans of the mechanistic approach to activate cardiac muscle contractility and support the further development of the drug as a potential treatment for heart failure.
Amgen holds an exclusive, worldwide (excluding Japan) licence for omecamtiv mecarbil and related compounds, subject to the specified development and commercialisation participation rights of Cytokinetics.
Cytokinetics and its partner Amgen are discussing plans for the initiation of additional studies designed to assess the safety, tolerability and pharmacokinetics of multiple oral formulations of omecamtiv mecarbil, to occur first in healthy volunteers and then in stable heart failure patients.
